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Long-Term Results After a
Telephone Intervention in Chronic Heart Failure
DIAL (Randomized Trial of Phone Intervention
in Chronic Heart Failure) Follow-Up
Daniel Ferrante, MD, MSC, Sergio Varini, MD, Alejandro Macchia, MD, Saúl Soifer, MD,
Raul Badra, MD, Daniel Nul, MD, Hugo Grancelli, MD, Herna´n Doval, MD, on behalf of
the GESICA Investigators
Buenos Aires, Argentina
Objectives The purpose of this study was to assess the rate of death and hospitalization for heart failure (HF) 1 and 3 years
after a randomized trial of telephone intervention aimed to improve education and compliance in stable patients
with HF ended.
Background The long-term effects of HF programs are not well known.
Methods In all, 1,518 patients with HF were randomized into the DIAL (Randomized Trial of Phone Intervention in Chronic
Heart Failure). After completion of the trial, patients were followed up to 3 years to assess major outcomes.
Compliance with diet, weight control, and treatment was evaluated. The effect of the intervention on mortality
and HF hospitalizations was assessed using relative risk (RR), relative risk reduction, and Cox proportional haz-
ards model for adjusting by potential confounders.
Results The rate of death or hospitalization for HF was lower in the intervention group (37.2% vs. 42.6%, RR: 0.81, 95% confi-
dence interval [CI]: 0.69 to 0.96; p  0.013) 1 and 3 years (55.7% vs. 57.5%, RR: 0.88, 95% CI: 0.77 to 1.00;
p  0.05) after the intervention ended. This benefit was mainly caused by a reduction in admission for HF (28.5% vs.
35.1% after 3 years, RR: 0.72, 95% CI: 0.60 to 0.87; p  0.0004). Patients who showed improvement in 1 or more
of 3 key compliance indicators (diet, weight control, and medication) had lower risks of events.
Conclusions The benefit observed during the intervention period persisted and was sustained 1 and 3 years after the inter-
vention ended. This effect may be explained by the impact of the educational intervention on patients’ behavior
and habits. (J Am Coll Cardiol 2010;56:372–8) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.049c
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ceart failure (HF) remains a serious health problem because
f the sustained increase in prevalence, incidence, and high
ortality as well as the poor quality of life that this
ondition confers on patients (1–5). The decrease in the
uality of life is mainly related to the frequent hospital
dmissions. Furthermore, hospitalizations impose the most
elevant personal, social, and economic burdens related to
his syndrome (6). The majority of hospital admissions have
reventable causes such as diet and treatment noncompli-
nce, inappropriate social support, or delayed medical con-
ultation for symptoms of HF progression (7–9).
rom the GESICA (Grupo de Estudio en Investigacio´n Clı´nica en Argentina)
oundation, Buenos Aires, Argentina. This trial was not submitted originally to an
pen database, but the main trial was originally published in the British Medical
ournal in 2005.o
Manuscript received October 29, 2009; revised manuscript received March 5, 2010,
ccepted March 19, 2010.Different intervention programs based on comprehensive
are and regular follow-up by a multidisciplinary team have
ecently shown admission and cost reduction (10–17).
owever, most of this evidence comes from small, single-
enter, nonrandomized studies that use complex strategies
or high-risk populations (18,19). A recent review high-
ighted the poor quality of the evidence that most of these
rograms had led so far (20).
See page 379
Different questions arise regarding the most appropriate
trategies to implement these types of programs. Moreover, the
equired intensity, duration, and long-term effects of the
ntervention are still unknown. Previous studies have not
onducted long follow-ups to assess these potential benefits
ver time.
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July 27, 2010:372–8 The DIAL Follow-Up TrialIn this context, DIAL (Randomized Trial of Phone
ntervention in Chronic Heart Failure) (21,22) offers a
nique opportunity to study both the long-term effective-
ess of the interventions and the potential mechanisms by
hich these interventions provide favorable results.
ethods
tudy design. The design and results of the DIAL trial
ave been reported elsewhere (21,22). Briefly, the study was
randomized, controlled, open-label, multicenter trial that
ompared a centralized regular phone intervention versus
sual care in outpatients with stable, chronic HF. Patients
ere recruited from 51 participating centers in Argentina.
The protocol was approved by internal review boards of
ach participating institution. All patients provide a signed
nformed consent at inclusion. For those patients who did
ot agree to receive the intervention, we used the intention-
o-treat analysis (Zelen criterion) (23).
ntervention. Patients assigned to the intervention group
eceived an explanatory booklet at randomization and were
ollowed up with a telephone intervention by specialized
urses. The objectives of the intervention were to improve diet
nd treatment compliance, to promote exercise, to regularly
onitor symptoms, weight, and edema, and to promote early
isits if signs of clinical deterioration were detected.
Nurses could adjust diuretic dose and suggest unsched-
led visits to the attending cardiologist. Patients were
nitially called every 14 days, and after the fourth call, the
requency could be adjusted according to the severity of each
ase and patient compliance. More severe and less compli-
nt patients received more calls according to pre-established
riteria (22). Nurses were not allowed to up-titrate medica-
ion. They were only allowed to adjust short-term changes in
iuretics, under supervision by the attending cardiologist (22).
Subjects in the control group continued treatment with
heir cardiologist in the same manner as the intervention
roup, except for the phone calls and the explanatory
ooklet.
nd points. The primary end point of the study was the
ate of all-cause mortality or hospital admissions for HF 1
ear after randomization.
Hospital admission for HF was defined as the presence of
ongestive HF at admission and the need of specific
reatment for at least 24 h.
All events were assigned by a committee blinded to
andomization status.
he DIAL study extended follow-up. The objective of
his extended study was to determine the rate of death or
ospitalization for HF, and the occurrence of each single
omponent of this composite end point, 1 and 3 years after
he intervention ended (e.g., 2 and 4 years after randomiza-
ion). To assess the potential decrease in effectiveness of the
ntervention after being discontinued, because the main trial
as stopped, and interaction of the time and interventiontatus, we used Cox regression analysis to test for time bependency. Additionally, we as-
essed whether patients with
arly improved compliance with
iet, weight control, and medica-
ion showed greater long-term
enefits.
tatistical analysis. Characteris-
ics of patients with and without
ntervention are reported as per-
entages and mean  SD and
ompared with the Pearson chi-square test and t test for
ategorical and continuous variables, respectively.
All analyses were performed by intention to treat. The
rimary end point was assessed using the log-rank test and
epicted using Kaplan-Meier curves. The effect of the
ntervention is reported using relative risk (RR) and relative
isk reduction (RRR), and tested using log-rank tests,
onsidering person-time incidence rates. These analyses
ere done both at the end of the trial and at 1 and 3 years
fter the intervention ended.
To assess a potential time-dependent effect of the inter-
ention, particularly a progressive decrease of effectiveness
cross time, a Cox proportional hazards model was used
ncluding the intervention as a time-dependent variable.
esults are expressed as hazard ratio (HR) and 95% confi-
ence interval (CI) (24,25).
To assess the impact of adherence improvement, the
hange in adherence was determined from the first visit and
rom the first telephone call until the first 45 days of
ntervention. Patients were categorized as having improved
dherence in 3 areas: diet, weight control, and medication.
ntervention patients were classified as having improved in
o indicator, 1 indicator, 2 indicators, or 3 indicators. The
dherence indicators were derived from the questionnaire
pplied at every telephone call to the patients. At each call,
urses addressed if the patient complied always, sometimes,
r never since the last call in prescribed medications, diet,
nd daily weighting.
The log-rank test was used to test the null hypothesis of
o difference between groups, and Kaplan-Meier curves
ere constructed. These variables were included in a Cox
egression model to assess the impact of adherence in the
rimary end point and HF admissions 3 years after follow-
p, adjusting for potential confounders. In all analyses, a
value 0.05 was considered statistically significant.
esults
aseline characteristics of patients. In all, 1,518 patients
ere randomized between June 2000 and November 2001.
f these, 760 patients were assigned to the intervention
roup and 758 to the control group.
Overall, from the 760 who were offered the intervention,
0 patients refused the intervention, although they agreed to
Abbreviations
and Acronyms
CI  confidence interval
HF  heart failure
HR  hazard ratio
RR  relative risk
RRR  relative risk
reductione contacted for follow-up. The study ended on August 1,
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The DIAL Follow-Up Trial July 27, 2010:372–8002, with the confirmation of at least 400 primary end
oints.
Both groups were similar at baseline (Table 1) (22). Mean
ge was 65 years; 71% were male and 29% were female; 93%
ere on a regimen of angiotensin-converting enzyme inhib-
tors or angiotensin-II receptor blockers, and 62% were
eceiving beta-blocker therapy. Most patients were in func-
ional class II or III, and approximately 80% showed left
entricular systolic dysfunction.
The mean follow-up duration at the end of the main
tudy was 16 months, ranging from 1 to 27 months. Overall
ollow-up was 57 months from the beginning of the trial (16
onths during the trial and 41 months after the trial),
anging from 1 to 84 months.
ffect of the intervention during the trial. At the end of
he study, the primary end point (combined rate of death or
ospitalization for HF) occurred in 200 (26.3%) patients in
he intervention group and in 235 (31%) in the control
roup (RRR: 20%, 95% CI: 3% to 34%, p  0.026).
aplan-Meier survival curves started to separate before 3
onths of follow-up. At day 180 and at 1 year, the RR was
.63 (95% CI: 0.47 to 0.85, p  0.0016) and 0.75 (95% CI:
.60 to 0.93, p  0.009), respectively.
The effect of the intervention on the primary end point
as driven by a reduction in the rate of hospitalizations for
F. A total of 128 (16.8%) patients randomly assigned to
Baseline Clinical Characteristics and TreatmentTable 1 Baseline Clinical Characteristics an
Characteristic
Age, yrs
Male
Heart rate, beats/min
Systolic blood pressure, mm Hg
Functional class III or IV
Sinus rhythm
Atrial fibrillation
Hypertension
Diabetes mellitus
HF hospital admissions year before
Previous angina or MI
History of ventricular tachycardia, ventricular fibrillation,
or sudden death
Left systolic dysfunction
Normal/mild, 40%
Moderate/severe, 40%
Medical treatment at randomization
Diuretics
Digoxin
Amiodarone
Spironolactone
ACEI
ARB
Beta-blockers
Values are mean  SD or %.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensihe intervention group and 169 (22.3%) randomly assigned io the control group had an admission for HF (RRR: 29%,
5% CI: 9% to 44%, p 0.005) with no significant effect on
ortality (RRR: 5%, 95% CI: 27% to 23%, p  0.69).
At the end of the trial, significantly more patients in the
ntervention group compared with the control group were
aking beta-blockers (59.2% and 51.6%, p  0.003), spi-
onolactone (27.2% and 22.6%, p  0.03), digoxin (33.4%
nd 28.6%, p  0.04), and furosemide (77.3% and 70.5%,
 0.007), and a similar trend was observed in the use of
ngiotensin-converting enzyme inhibitors (78.3% and
5.8%, p  0.24). However, prescription patterns retrieved
y physicians were similar between groups (data not shown).
Patients randomly allocated to the intervention group
eported higher scores in the Minnesota Living with Heart
ailure Questionnaire (scores from 0 to 105: 0 indicates no
hanges in quality of life, and 105 indicates a maximum
lteration), both in the global scores (30.6 vs. 35.0, p 
.001) and in the physical domain (11.2 vs. 12.8, p 0.007)
nd emotional domain (6.7 vs. 7.9, p 0.002). The median
f ambulatory visits per year in both groups was 4.
ost-trial effects of intervention. The clinical benefit of
he intervention remained 1 and 3 years after the trial
eriod. One year after the intervention ended, there was a
9% reduction in the incidence of the primary end point
p 0.013) and at 3 years, a 12% significant reduction (p
.05) (Table 2). This effect was caused by a reduction in the
atment
ervention Group
(n  760)
Control Group
(n  758)
Total
(n  1,518)
64.8 13.9 65.2 12.7 65.0 13.3
72.6 68.9 70.8
73.7 18.5 75.7 15.4 74.7 17.0
124.0 25.2 124.7 23.5 124.4 24.4
50.0 48.8 49.4
71.4 72.3 71.9
19.2 18.8 18.9
59.7 58.4 59.1
20.3 21.2 20.8
35.1 38.8 37.0
43.4 45.3 44.3
6.0 5.0 5.6
21.5 19.6 20.4
78.5 80.4 79.6
82.1 83.5 82.8
45.4 48.5 47.0
29.2 28.9 29.1
31.4 33.0 32.2
78.0 81.1 79.6
14.5 12.1 13.3
61.1 62.3 61.6
tor blocker; HF  heart failure; MI  myocardial infarction.d Tre
Intncidence of hospital admissions for HF: 174 HF admis-
s
C
H
0
a
(
p
a
0
t
i
n
fi
t
p
s
C
(
2
c
a
8
p
w
f
w
g
1
i
w
t
a
m
a
i
i
t
b
r
f
c
t
a
t
m
i
p
0
H
O
w
t
a
w
w
t
D
D
f
H
(
c
t
n
m
p
H
i
b
t
a
H
e
e
H
d
c
L
V
375JACC Vol. 56, No. 5, 2010 Ferrante et al.
July 27, 2010:372–8 The DIAL Follow-Up Trialions (22.9%) versus 220 admissions (29.0%; RR: 0.73, 95%
I: 0.60 to 0.90, p  0.002) occurred 1 year after, and 217
F admissions (28.9%) versus 266 admissions (35.1%; RR:
.72, 95% CI: 0.60 to 0.87, p  0.0004) occurred 3 years
fter for the intervention and the control group, respectively
Table 2, Fig. 1). All-cause mortality was the same between
atients randomly assigned to the intervention and patients
ssigned to the control group at 1 year (RR: 0.94, 95% CI:
.77 to 1.16, p 0.59) and 3 years (RR: 1.02, 95% CI: 0.87
o 1.20, p  0.73), respectively (Table 2, Fig. 1).
In the Cox time-dependent regression model, with the
nclusion of the intervention as a time-dependent variable,
o significant interaction was observed at follow-up. This
nding shows a persistence of the effect of similar magni-
ude (HR) during the entire follow-up (Fig. 1). Also,
roportionality hazards were maintained between groups,
uggesting a persistent effect in time.
ompliance. Of 760 patients in the intervention group, 69
9.1%) did not improve compliance during the first 45 days,
96 (38.9%) improved only in 1 indicator (diet, weight
ontrol, or medication), 277 (36.4%) improved 2 indicators,
nd 118 (15.5%) improved in all 3 indicators. Overall,
2.8% improved in medication compliance, 40.7% im-
roved in diet compliance, and 34.9% improved in daily
eight control.
Considering the primary end point after 3 years of
ollow-up, the cumulative incidence in the control group
as 57.5% (n  436), 65.2% (n  45) in the intervention
roups with no improvement in compliance, 57.4% (n 
70) in the intervention group with improvement in 1
ndicator, 52.3% (n  145) in the intervention group
ith improvement in 2 indicators, and 53.4% (n  63) in
he intervention group with improvement in all 3 compli-
nce indicators (log-rank test p  0.041). Differences were
ore significant when admission for HF was considered as
n end point: control group, 35.1%; intervention without
mprovement, 33.3%; with 1 indicator, 33.1%; with 2
ndicators, 27.1%; and with all 3 indicators, 17.8% (log-rank
est p  0.0009) (Fig. 2). These differences persisted after
eing adjusted by other potential confounders in the Cox
egression analyses (sex, age, New York Heart Association
unctional class, diabetes mellitus, previous admissions,
ong-Term End PointsTable 2 Long-Term End Points
End Point Intervention
Beginning of study up to 1 yr after completion
Primary end point 283 (37.2)
Heart failure 174 (22.9)
Death 189 (24.9)
Beginning of trial up to 3 yrs after completion
Primary end point 423 (55.7)
Heart failure 217 (28.5)
Death 326 (42.9)
alues are n (%) unless otherwise noted.
CI  confidence interval; RR  relative riskhronic obstructive pulmonary disease, systolic dysfunction): ohe HR for the intervention group categorized by compli-
nce versus the control group for HF admission according
o compliance improvement were as follows: no improve-
ent, HR: 0.91 (95% CI: 0.59 to 1.40, p  0.67); 1
ndicator improvement, HR: 0.87 (95% CI: 0.69 to 1.10,
 0.25); 2 indicators improvement, HR: 0.71 (95% CI:
.55 to 0.92, p  0.012); and 3 indicators improvement,
R: 0.44 (95% CI: 0.28 to 0.69, p  0.001).
ther effects. At the end of follow-up, functional capacity
as better in the intervention group (8.07% deteriorated in
heir functional class, 64.44% remained without changes,
nd 27.48% improved) than in the control group (39.31%
ith deterioration, 39.31% without changes, and 21.38%
ith improvement; p  0.0001).
There was no significant change in blood pressure be-
ween groups during the trial period and follow-up.
iscussion
espite a number of clinical trials showed a short-term
avorable effect of management programs for patients with
F (18,19), as already recognized in systematic reviews
20), most of these trials were small, conducted in selected
enters, and had many methodological weaknesses. Addi-
ionally, no trial provided information about the effective-
ess of these interventions on a long-term follow-up period.
To our knowledge, the DIAL trial is the first randomized
ulticenter study that assessed the effect of a simple,
ragmatic, telephone intervention in a large population with
F that also has a long-term follow-up. This is particularly
mportant as the benefit of follow-up programs has only
een observed during their implementation.
The main result of this extension of the DIAL trial is that
his simple, nurse-based telephone intervention was associ-
ted with a clear clinical benefit for patients with chronic
F 1 and 3 years after the intervention stopped. This
ducation and monitoring based strategy was particularly
ffective in reducing the incidence of hospital admissions for
F. The benefit and the magnitude of benefit observed
uring the intervention remained in the midterm after the
onclusion of the telephone follow-up with a similar effect
Control RR (95% CI) p Value
323 (42.6) 0.81 (0.69–0.96) 0.013
220 (29.0) 0.73 (0.60–0.90) 0.002
197 (25.9) 0.94 (0.77–1.16) 0.586
436 (57.5) 0.88 (0.77–1.00) 0.05
266 (35.1) 0.72 (0.60–0.87) 0.0004
308 (40.6) 1.02 (0.87–1.20) 0.73ver time.
s
i
s
a
a
a
c
w
t
f
I
t
t
i
p
f
t
i
376 Ferrante et al. JACC Vol. 56, No. 5, 2010
The DIAL Follow-Up Trial July 27, 2010:372–8Why did we observe a sustained effect after the conclu-
ion of the intervention? The mainstay of the telephone
ntervention were both patient monitoring and education
trategies aimed at improving treatment and diet compli-
nce and self-monitoring of HF signs and symptoms,
llowing early consultation.
This benefit may be related to a change of patients’ habits
nd behaviors, as that is suggested by the improved patient
ompliance rate at the end of the study. Also, the intervention
as associated with a quality of life improvement, not only in
Figure 1 Kaplan-Meier Survival Estimates
Primary end point (A) and admissions for heart failure (B) at follow-up. The solid linehe disease-related physical aspects but also in the emotional hactors that could have contributed to increased compliance.
mproved compliance during the early stages of the interven-
ion was related to a greater benefit up to 3 years after
ermination of the trial. The beneficial mechanism of the
ntervention can be partially explained by this change of
atients’ habits, mainly influenced by the nurses’ interventions
ocused on education, self-management, and monitoring.
Furthermore, the analysis of events after the conclusion of
he intervention shows that the benefit is maintained in the
ntervention group. This effect persistence shows that be-
es control group; the dashed line indicates intervention group. HR  hazard ratio.indicatavioral changes secondary to education can be the main
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July 27, 2010:372–8 The DIAL Follow-Up Trialechanism of action, explaining the benefits of this
ntervention and that this methodology empowers the
atients.
The lower event rate observed in this trial as compared
ith other studies that tested similar interventions may be
xplained by the inclusion criteria of the trial. The DIAL
rial randomized stable outpatients with optimized therapy
t enrollment. Other trials included post-discharge patients
ithout optimal treatment, and part of their benefit might
e related to an improvement in drug prescription in a
igher risk population. Differences observed in medication
se were explained by increased adherence, because pre-
cription patterns were similar between groups. A higher use
f beta-blockers and spironolactone could have explained
art of the benefit observed, but this increase was not related
o an intensified treatment but was due to a higher compli-
nce. That highlights even more the findings of the DIAL
rial, putting into perspective that this simple and pragmatic
ntervention was able to reduce HF admissions on top of the
est medical treatment available.
Another important aspect that should be considered is
he external validity of these results. This was a simple,
ow-cost intervention, $90 per patient per year, easily
erformed with different types of patients and centers.
oreover, the benefit observed in this study could be even
igher among patients with HF treated by generalists.
ptimal compliance was low in these patients (15%), and
ore efforts should be allocated to effective strategies to
mprove adherence.
One of the limitations of the study could be a potential
iased classification of events due to an open trial design. To
Figure 2 Kaplan-Meier Survival Estimates by Compliance
Admission for heart failure according to compliance indicators: diet, weight control
the intervention group, the dashed line represents 1 indicator, the dotted line repvoid this, an event committee blindly classified each eventefore the analysis. Also because of the open design, head
hysicians could have intensified care for patients assigned
o the intervention. However, this was unlikely because drug
rescription was similar for both groups during the whole
tudy, and we found no differences in the number of
utpatient visits (22).
onclusions
he clinical evolution of optimally treated patients with HF
an improve with the implementation of follow-up pro-
rams based on simple and low-cost interventions. This
ype of education and monitoring programs may provide
ustained clinical benefits, having a strong impact in
atients’ behavior. Patients who change their behavior
arly during the intervention are at lower risk of events.
n the light of the available evidence, the implementation
f these programs could become a standard of care for
atients with HF.
eprint requests and correspondence: Dr. Daniel Ferrante, GE-
ICA Foundation, Avenida Rivadavia 2358, 1 Piso, Departamento 4,
uenos Aires 1034, Argentina. E-mail: dferrante@fundaciongesica.org.
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